Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfadoxine + pyrimethamine + folic acid
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of the antimalarial drugs sulfadoxine and pyrimethamine with folic acid supplementation. Sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase, both interfering with folate metabolism in the malaria parasite. Folic acid is added to prevent neural tube defects in pregnant women while maintaining antimalarial efficacy. The efficacy of sulfadoxine-pyrimethamine can be reduced by high doses of folic acid (≥5 mg), but lower doses (0.4-0.8 mg) do not significantly affect treatment outcomes.
02
Targets
DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on sulfadoxine + pyrimethamine + folic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfadoxine + pyrimethamine + folic acid.